FDA-cleared profile

RUS

Hutom Inc. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: RUS processes CT images for trained professionals using organ and vessel segmentation, pneumoperitoneum estimation, measurements, paths, and two- or three-dimensional visualization to support reporting and treatment or surgical planning.

Clinical role
CT-based anatomical segmentation, 3D reconstruction, measurement, and patient-specific surgical-planning support.
Images and patients
CT/CTA · Chest/Abdomen
Key limitation
Keep in mind: This product is not intended for use with or for the primary diagnostic interpretation of Mammography images. Surgical planning in RUS does not replace actual surgery and can only be used as an auxiliary tool. The clinician is solely responsible for making all final patient management decisions.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: RUS processes CT images for trained professionals using organ and vessel segmentation, pneumoperitoneum estimation, measurements, paths, and two- or three-dimensional visualization to support reporting and treatment or surgical planning.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Chest/Abdomen Input: DICOM CT image studies received through configured storage or network services.
  • Who uses it?Intended users: Trained healthcare professionals reading, interpreting, reporting, or planning treatment from CT images.
  • What does the software produce?Output: Basic 2D viewing, volume rendering and 3D volume viewing, image fusion, surface rendering, measurements, reporting, organ-segment detection and labeling, path definition through vascular structures, segmentation of visible bones, organs, vascular structures, and skin, and pneumoperitoneum generated by a model.
  • What is its most important limitation?Key limitation: This product is not intended for use with or for the primary diagnostic interpretation of Mammography images. Surgical planning in RUS does not replace actual surgery and can only be used as an auxiliary tool. The clinician is solely responsible for making all final patient management decisions.

Clinical takeaway. Clinical role: RUS processes CT images for trained professionals using organ and vessel segmentation, pneumoperitoneum estimation, measurements, paths, and two- or three-dimensional visualization to support reporting and treatment or surgical planning.

Evidence takeaway. Evidence from the reviewed source record: Exact-submission testing used 60 patient CT studies with institution-level separation. Organ and vessel Dice and pneumoperitoneum error met prespecified targets. A 2026 prospective multicenter lung-segmentectomy study adds product-family implementation evidence.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
RUS processes CT images for trained professionals using organ and vessel segmentation, pneumoperitoneum estimation, measurements, paths, and two- or three-dimensional visualization to support reporting and treatment or surgical planning.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.

Workflow role
CT-based anatomical segmentation, 3D reconstruction, measurement, and patient-specific surgical-planning support.
  • Exact FDA submission
  • Checked 2026-09-03
Required input
DICOM CT image studies received through configured storage or network services.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Output and clinician action
Basic 2D viewing, volume rendering and 3D volume viewing, image fusion, surface rendering, measurements, reporting, organ-segment detection and labeling, path definition through vascular structures, segmentation of visible bones, organs, vascular structures, and skin, and pneumoperitoneum generated by a model.
  • Exact FDA submission
  • Checked 2026-09-19

The exact text supports these visualization, segmentation, path, measurement, reporting, and pneumoperitoneum functions but does not mention airway output.

Care setting
Hospital clinical image-review and surgical-planning environments.
  • Exact FDA submission
  • Checked 2026-09-03
Intended users
Trained healthcare professionals reading, interpreting, reporting, or planning treatment from CT images.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Limitations
This product is not intended for use with or for the primary diagnostic interpretation of Mammography images. Surgical planning in RUS does not replace actual surgery and can only be used as an auxiliary tool. The clinician is solely responsible for making all final patient management decisions.
  • Exact FDA submission
  • Checked 2026-09-19

The exact packet directly states the mammography exclusion, auxiliary surgical-planning role, and clinician responsibility; the current product-family lung-surgery sentence is not in the packet.

Evidence summary
Exact-submission testing used 60 patient CT studies with institution-level separation. Organ and vessel Dice and pneumoperitoneum error met prespecified targets. A 2026 prospective multicenter lung-segmentectomy study adds product-family implementation evidence.
  • Exact FDA submission
  • Checked 2026-09-03

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Exact-submission testing used 60 patient CT studies with institution-level separation. Organ and vessel Dice and pneumoperitoneum error met prespecified targets. A 2026 prospective multicenter lung-segmentectomy study adds product-family implementation evidence.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03
Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Sensitivity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or dose-delivery function. Use the task-specific endpoints and tested population reported below.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Specificity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or dose-delivery function. Use the task-specific endpoints and tested population reported below.

Organ segmentation Dice

0.927 DSC

  • EndpointOrgan segmentation versus reference
  • PopulationRUS
  • Tested versionRUS cleared in K233457

Vessel segmentation Dice

0.92 DSC

  • EndpointVessel segmentation versus reference
  • PopulationRUS
  • Tested versionRUS cleared in K233457

Pneumoperitoneum mean absolute error

0.972 mm

  • EndpointEstimated versus reference pneumoperitoneum
  • PopulationRUS
  • Tested versionRUS cleared in K233457

K233457 FDA performance package for RUS

  • DesignManufacturer independent CT performance verification of three locked models against reference annotations
  • Population60 patient CT studies separated from model development at the institution level
  • Scopeexact submission
  • Tested versionRUS cleared in K233457
  • Samplen=60
  • IndependenceSponsor or vendor study

K233457

Manufacturer evidence submitted for substantial equivalence; local clinical, technical, and workflow acceptance remains necessary.

Patient-specific virtual surgical navigation for lung segmentectomy

  • DesignProspective multicenter clinical evaluation
  • PopulationPatients undergoing lung segmentectomy with RUS planning support
  • Scopeproduct family
  • Tested versionRUS product family; exact K233457 build not established
  • IndependenceIndependent study

DOI 10.3389/fonc.2026.1774607

Product-family implementation evidence; abstract exact outcomes before publishing numerical claims.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K233457 by exact submission identifier.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03

A zero-result exact-identifier search does not prove that no recall, correction, adverse-event report, or product-family safety signal exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the device within the applicable imaging or surgical service line and verify payer, site-of-service, and coding assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM CT image studies received through configured storage or network services.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K233457: RUS

  2. Routing

    Source context, not route validation: Windows PC software with DICOM SCP/SCU functions and 2D/3D visualization and reporting.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-03 · FDA K233457: RUS · RUS surgical planning software · Prospective multicenter evaluation of patient-specific virtual surgical navigation for lung segmentectomy

  3. AI processing

    Source context, not route validation: On-premises Windows workstation or server configuration described for the cleared software.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-03 · FDA K233457: RUS · RUS surgical planning software · Prospective multicenter evaluation of patient-specific virtual surgical navigation for lung segmentectomy

  4. Returned objects

    Source context, not route validation: Basic 2D viewing, volume rendering and 3D volume viewing, image fusion, surface rendering, measurements, reporting, organ-segment detection and labeling, path definition through vascular structures, segmentation of visible bones, organs, vascular structures, and skin, and pneumoperitoneum generated by a model.

    Scope: Exact FDA submission. The exact text supports these visualization, segmentation, path, measurement, reporting, and pneumoperitoneum functions but does not mention airway output.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K233457: RUS

  5. Viewer/worklist/report

    Unresolved route: Basic 2D viewing, volume rendering and 3D volume viewing, image fusion, surface rendering, measurements, reporting, organ-segment detection and labeling, path definition through vascular structures, segmentation of visible bones, organs, vascular structures, and skin, and pneumoperitoneum generated by a model.

    Scope: Exact FDA submission. The exact text supports these visualization, segmentation, path, measurement, reporting, and pneumoperitoneum functions but does not mention airway output.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K233457: RUS

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
On-premises Windows workstation or server configuration described for the cleared software.
  • Exact FDA submission
  • Checked 2026-09-03
Integration
Windows PC software with DICOM SCP/SCU functions and 2D/3D visualization and reporting.
  • Exact FDA submission
  • Checked 2026-09-03
Training
Only trained healthcare professionals reading, interpreting, reporting, or planning treatment from ct images. should operate or interpret the system. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-03
Monitoring
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: RUS is CT-only in K233457. Three models have distinct endpoints, and all automated outputs require professional review. Current lung-surgery research is product-family clinical evidence, not exact-release validation.
  • Exact FDA submission
  • Checked 2026-09-03

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, and outputs to K233457 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

Windows PC software with DICOM SCP/SCU functions and 2D/3D visualization and reporting.

exact submission · checked 2026-09-03

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. RUS is CT-only in K233457. Three models have distinct endpoints, and all automated outputs require professional review. Current lung-surgery research is product-family clinical evidence, not exact-release validation.

exact submission · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-03

Vendor productivity claims are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: RUS is CT-only in K233457. Three models have distinct endpoints, and all automated outputs require professional review. Current lung-surgery research is product-family clinical evidence, not exact-release validation.

exact submission · checked 2026-09-03

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K233457
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

The exact indication specifies iodine contrast-enhanced abdomen CT and does not establish the broader CT/CTA value. Controlled directory display reconciled from exact FDA wording: Iodine contrast-enhanced abdomen CT. -> CT/CTA.

Anatomy
Chest/Abdomen
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

The exact packet specifies abdomen CT and names abdominal organs and vascular structures; it does not establish a chest scope. Controlled directory display reconciled from exact FDA wording: Abdomen (including liver, stomach, spleen, gallbladder, pancreas, and vessels). -> Chest/Abdomen.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-07-12
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
12Source classes checked
20Screened PubMed leads
10Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 20 PubMed and 10 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 20 PubMed and 10 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, vendor product page, peer reviewed publication, reimbursement policy, fda device recall, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, enabled features, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-03 - Exact FDA submission

    Public materials reviewed for this batch do not establish the complete security posture for the exact release. Request data-flow, identity, audit, encryption, retention, support-access, vulnerability-management, backup, and incident-response evidence.

  • Installation timeline: Not yet reviewed

8 sources - 3 history items

Source ledger

  1. FDA K233457: RUS

    U.S. Food and Drug Administration - Published 2024-07-12 - Accessed 2026-09-19

    Scope: purpose, intendedUsers, input, modality, anatomy, output, limitations, evidenceSummary, clinicalUse

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. RUS surgical planning software

    Hutom - Accessed 2026-09-03

    Scope: productFamily, workflowRole, integration, deployment, implementationCapabilities, currentCommercialContext

  8. Prospective multicenter evaluation of patient-specific virtual surgical navigation for lung segmentectomy

    Frontiers in Oncology - Accessed 2026-09-03

    Scope: limitations, evidenceSummary, evidenceStudy, implementationCapabilities, monitoring

Research history

  1. K233457 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K260406

Brainomix 360 Hyperdensity

Brainomix Limited

Authorized purpose: Provides volumetric hyperdensity segmentation and quantification as an aid; physicians must review original images.

Modality
CT/CTA
Anatomy
Brain
Decision
2026-06-12
FDA-cleared K260322

Acorn 3D Software (AC-SEG-4009); Acorn 3DP Model (AC-101-XX)

Mighty Oak Medical

Authorized purpose: Acorn 3D Software and Acorn 3DP Model process CT, synthetic CT, and CT angiography for segmentation, visualization, measurement, treatment planning, and three-dimensional printing, including adult and pediatric spine trajectory planning.

Modality
CT/CTA
Anatomy
Spine; craniomaxillofacial; musculoskeletal anatomy; and patient-specific printed models
Decision
2026-06-11

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history